{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IgA+Nephropathy+%28IgAN%29&page=4",
    "query": {
      "condition": "IgA Nephropathy (IgAN)",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 76,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IgA+Nephropathy+%28IgAN%29&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IgA+Nephropathy+%28IgAN%29&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-10T06:54:45.899Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06419205",
      "title": "A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Nephropathy",
        "Lupus Nephritis (LN)",
        "C3 (Complement Component 3) Glomerulopathy"
      ],
      "interventions": [
        {
          "name": "ADX-097",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akebia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-07-30",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-10T06:54:45.899Z",
      "location_count": 3,
      "location_summary": "Hollywood, Florida • Lawrenceville, Georgia • Orangeburg, South Carolina",
      "locations": [
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Orangeburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06419205"
    },
    {
      "nct_id": "NCT04042623",
      "title": "Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Nephropathy"
      ],
      "interventions": [
        {
          "name": "AVB-S6-500",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aravive, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2019-11-27",
      "completion_date": "2020-08-01",
      "has_results": true,
      "last_update_posted_date": "2022-02-10",
      "last_synced_at": "2026-10-10T06:54:45.899Z",
      "location_count": 1,
      "location_summary": "Doral, Florida",
      "locations": [
        {
          "city": "Doral",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04042623"
    },
    {
      "nct_id": "NCT07182227",
      "title": "PS-002 for the Treatment of IgA Nephropathy in Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A (IgA) Nephropathy"
      ],
      "interventions": [
        {
          "name": "PS-002",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Purespring Therapeutics Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2026-03-30",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-10T06:54:45.899Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Baltimore, Maryland",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07182227"
    },
    {
      "nct_id": "NCT04573920",
      "title": "Atrasentan in Patients With Proteinuric Glomerular Diseases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgA Nephropathy",
        "Focal Segmental Glomerulosclerosis",
        "Alport Syndrome",
        "Diabetic Kidney Disease",
        "Diabetic Nephropathy Type 2",
        "Immunoglobulin A Nephropathy"
      ],
      "interventions": [
        {
          "name": "Atrasentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2021-03-15",
      "completion_date": "2026-10-27",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-10T06:54:45.899Z",
      "location_count": 14,
      "location_summary": "Glendale, California • Los Angeles, California • San Dimas, California + 11 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Dimas",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04573920"
    },
    {
      "nct_id": "NCT05174221",
      "title": "A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Disease",
        "Glomerulonephritis"
      ],
      "interventions": [
        {
          "name": "Mezagitamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2022-08-16",
      "completion_date": "2025-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-10-10T06:54:45.899Z",
      "location_count": 3,
      "location_summary": "Northridge, California • Nampa, Idaho • Evanston, Illinois",
      "locations": [
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Nampa",
          "state": "Idaho"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05174221"
    },
    {
      "nct_id": "NCT07219121",
      "title": "Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Proteinuria",
        "Immunoglobulin A (IgA) Nephropathy",
        "Focal Segmental Glomerulosclerosis",
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Sparsentan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Travere Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2025-10-07",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-10T06:54:45.899Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • New York, New York • Morrisville, North Carolina + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Morrisville",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219121"
    },
    {
      "nct_id": "NCT01835639",
      "title": "Vitamin D Supplementation in Glomerular Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glomerular Disease"
      ],
      "interventions": [
        {
          "name": "Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "5 Years to 30 Years"
      },
      "enrollment_count": 32,
      "start_date": "2013-04",
      "completion_date": "2017-09",
      "has_results": false,
      "last_update_posted_date": "2019-08-12",
      "last_synced_at": "2026-10-10T06:54:45.899Z",
      "location_count": 5,
      "location_summary": "Wilmington, Delaware • Baltimore, Maryland • New Hyde Park, New York + 1 more",
      "locations": [
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01835639"
    },
    {
      "nct_id": "NCT06989359",
      "title": "Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgAN",
        "C3G",
        "Complement-mediated Kidney Disease",
        "IgA Nephropathy (IgAN)",
        "IC-MPGN"
      ],
      "interventions": [
        {
          "name": "ADX-038 Dose Level 2",
          "type": "DRUG"
        },
        {
          "name": "ADX-038 Dose Level 1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ADARx Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2025-08-28",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-10T06:54:45.899Z",
      "location_count": 11,
      "location_summary": "Doral, Florida • Miami, Florida • Pembroke Pines, Florida + 8 more",
      "locations": [
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06989359"
    },
    {
      "nct_id": "NCT07024563",
      "title": "Study of Ravulizumab in Pediatric Participants With Primary IgAN",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "IgAN",
        "IgAVN",
        "Immunoglobulin A Nephropathy",
        "Immunoglobulin A Vasculitis Associated Nephritis",
        "Henoch-schonlein Purpura Nephritis",
        "IgA Vasculitis"
      ],
      "interventions": [
        {
          "name": "Ravulizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 36,
      "start_date": "2025-06-14",
      "completion_date": "2030-04-19",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-10-10T06:54:45.899Z",
      "location_count": 2,
      "location_summary": "Palo Alto, California • Aurora, Colorado",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07024563"
    },
    {
      "nct_id": "NCT06994845",
      "title": "Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immunoglobulin A Nephropathy (IgAN)"
      ],
      "interventions": [
        {
          "name": "iptacopan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 31,
      "start_date": "2025-11-27",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-10T06:54:45.899Z",
      "location_count": 5,
      "location_summary": "Madera, California • Aurora, Colorado • Gainesville, Florida + 2 more",
      "locations": [
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06994845"
    }
  ]
}